Mi­rati's KRAS drug looks like the ear­ly fa­vorite in colon can­cer with new da­ta, putting the pres­sure square on Am­gen

With Am­gen al­ready pro­vid­ing proof-of-con­cept for KRAS in­hibitors with its so­tora­sib, Mi­rati Ther­a­peu­tics is piec­ing to­geth­er a fol­low-up ef­fort in lung can­cer with da­ta it thinks are su­pe­ri­or. But in colon can­cer, where so­lo so­tora­sib has turned in a dud, Mi­rati may now have a strong case for su­pe­ri­or­i­ty.

Mi­rati’s ada­gra­sib, dosed so­lo or in com­bi­na­tion with chemother­a­py ce­tux­imab, showed nu­mer­i­cal­ly high­er re­sponse rates than so­tora­sib so­lo and as part of a com­bi­na­tion study in a sim­i­lar pa­tient pop­u­la­tion al­so re­vealed this week at #ES­MO21. Mi­rati’s da­ta were pre­sent­ed as part of a co­hort up­date from the Phase II KRYS­TAL-1 study test­ing ada­gra­sib in a range of sol­id tu­mors har­bor­ing the KRAS-G12C mu­ta­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER